Biogen Strikes Alzheimer’s Deal, Paying $45M for Ionis Tau Drug Rights
Summary
In the latest development of a multi-drug and multi-disease collaboration, the company has licensed an experimental Ionis Pharmaceuticals compound that works in a different way than the therapies currently in its pipeline for neurodegenerative diseases. Under the deal, Ionis will handle the Phase 1 testing, which started in 2017, and a one-year extension study that began this year. Interest in amyloid has recently undergone a revival as a result of Biogen’s decision to ask the FDA to review its lead anti-amyloid Alzheimer’s drug, aducanumab. Ionis, based in Carlsbad, CA, and Biogen have a broad partnership with the aim of making new drugs to treat neurological disorders. The collaboration has already produced a commercial drug, nusinersen (Spinraza)—the first-ever treatment approved for spinal muscular atrophy—which was OK’d in 2016.
Classifications
AskAI Classifications
LabelsLinked Companies
